| Nome |
# |
|
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation, file e14ff6e6-0cbc-0209-e053-6605fe0ad24c
|
71
|
|
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial, file e14ff6e6-085a-0209-e053-6605fe0ad24c
|
69
|
|
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors, file e14ff6e5-f922-0209-e053-6605fe0ad24c
|
63
|
|
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies, file e14ff6e6-055e-0209-e053-6605fe0ad24c
|
58
|
|
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?, file e14ff6e6-03a3-0209-e053-6605fe0ad24c
|
55
|
|
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study, file e14ff6e6-0d53-0209-e053-6605fe0ad24c
|
51
|
|
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis, file e14ff6e6-00ba-0209-e053-6605fe0ad24c
|
50
|
|
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study, file e14ff6e6-0b13-0209-e053-6605fe0ad24c
|
48
|
|
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?, file e14ff6e6-0b79-0209-e053-6605fe0ad24c
|
47
|
|
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study, file e14ff6e5-fa73-0209-e053-6605fe0ad24c
|
44
|
|
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy, file e14ff6e6-0502-0209-e053-6605fe0ad24c
|
44
|
|
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report, file e14ff6e5-7e2d-0209-e053-6605fe0ad24c
|
43
|
|
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey, file e14ff6e5-f6ca-0209-e053-6605fe0ad24c
|
43
|
|
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017), file e14ff6e6-09f2-0209-e053-6605fe0ad24c
|
43
|
|
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers, file e14ff6e6-0df4-0209-e053-6605fe0ad24c
|
42
|
|
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs), file e14ff6e6-039e-0209-e053-6605fe0ad24c
|
41
|
|
Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin, file e14ff6e6-070d-0209-e053-6605fe0ad24c
|
41
|
|
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease, file e14ff6e4-b934-0209-e053-6605fe0ad24c
|
40
|
|
Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women, file e14ff6e6-0825-0209-e053-6605fe0ad24c
|
40
|
|
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer, file e14ff6e6-0871-0209-e053-6605fe0ad24c
|
38
|
|
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia, file e14ff6e6-03a1-0209-e053-6605fe0ad24c
|
33
|
|
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer, file e14ff6e5-fb4e-0209-e053-6605fe0ad24c
|
32
|
|
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib, file e14ff6e5-fe1e-0209-e053-6605fe0ad24c
|
31
|
|
Pan-cancer analysis of whole genomes, file e14ff6e4-fd7f-0209-e053-6605fe0ad24c
|
30
|
|
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer, file e14ff6e5-fe17-0209-e053-6605fe0ad24c
|
29
|
|
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study, file e14ff6e6-03b5-0209-e053-6605fe0ad24c
|
29
|
|
mTOR Cross-Talk in Cancer and Potential for Combination Therapy., file e14ff6e4-c95d-0209-e053-6605fe0ad24c
|
28
|
|
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients, file e14ff6e5-0362-0209-e053-6605fe0ad24c
|
28
|
|
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel, file e14ff6e6-0451-0209-e053-6605fe0ad24c
|
28
|
|
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up, file e14ff6e5-f798-0209-e053-6605fe0ad24c
|
27
|
|
Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma, file e14ff6e6-0d44-0209-e053-6605fe0ad24c
|
27
|
|
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer, file e14ff6e4-baa3-0209-e053-6605fe0ad24c
|
26
|
|
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function, file e14ff6e6-04f5-0209-e053-6605fe0ad24c
|
26
|
|
Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis, file e14ff6e6-0780-0209-e053-6605fe0ad24c
|
26
|
|
Exercise levels and preferences in cancer patients: a cross-sectional study, file e14ff6e5-24e9-0209-e053-6605fe0ad24c
|
25
|
|
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma, file e14ff6e6-0743-0209-e053-6605fe0ad24c
|
25
|
|
Role of mTOR Signaling in Tumor Microenvironment: An Overview, file e14ff6e4-c9a5-0209-e053-6605fe0ad24c
|
24
|
|
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures, file e14ff6e5-f796-0209-e053-6605fe0ad24c
|
24
|
|
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study), file e14ff6e5-fd63-0209-e053-6605fe0ad24c
|
24
|
|
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial, file e14ff6e6-0702-0209-e053-6605fe0ad24c
|
24
|
|
PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients, file e14ff6e6-0cff-0209-e053-6605fe0ad24c
|
24
|
|
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus, file e14ff6e6-0a5f-0209-e053-6605fe0ad24c
|
23
|
|
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors, file e14ff6e6-04fb-0209-e053-6605fe0ad24c
|
22
|
|
Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer, file e14ff6e6-0753-0209-e053-6605fe0ad24c
|
22
|
|
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort, file e14ff6e6-08cd-0209-e053-6605fe0ad24c
|
22
|
|
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors, file e14ff6e5-f81d-0209-e053-6605fe0ad24c
|
21
|
|
MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer, file e14ff6e5-f81f-0209-e053-6605fe0ad24c
|
21
|
|
Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer, file e14ff6e6-0b84-0209-e053-6605fe0ad24c
|
21
|
|
Oral microbiota in oropharyngeal cancers: friend or foe?, file 19cdcc0d-d6e3-4ae0-8e0d-434fc47b1300
|
20
|
|
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models, file e14ff6e4-c833-0209-e053-6605fe0ad24c
|
20
|
|
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study, file e14ff6e5-7664-0209-e053-6605fe0ad24c
|
20
|
|
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts, file e14ff6e6-0446-0209-e053-6605fe0ad24c
|
20
|
|
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back, file e14ff6e6-04e5-0209-e053-6605fe0ad24c
|
20
|
|
The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms, file e14ff6e6-082b-0209-e053-6605fe0ad24c
|
20
|
|
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia, file e14ff6e6-0bb5-0209-e053-6605fe0ad24c
|
20
|
|
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis, file e14ff6e6-0d62-0209-e053-6605fe0ad24c
|
20
|
|
Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies, file e14ff6e5-ffa0-0209-e053-6605fe0ad24c
|
19
|
|
Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments, file e14ff6e6-03bf-0209-e053-6605fe0ad24c
|
19
|
|
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies, file e14ff6e6-086c-0209-e053-6605fe0ad24c
|
19
|
|
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy, file e14ff6e5-a11f-0209-e053-6605fe0ad24c
|
18
|
|
A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma, file e14ff6e5-fbcb-0209-e053-6605fe0ad24c
|
18
|
|
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort, file e14ff6e5-fd61-0209-e053-6605fe0ad24c
|
18
|
|
Exercise and bone health in cancer: enemy or ally?, file ef93d7d5-75c2-4b5e-bc6f-5d40519873a2
|
18
|
|
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer, file e14ff6e6-083a-0209-e053-6605fe0ad24c
|
17
|
|
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine, file e14ff6e4-bc34-0209-e053-6605fe0ad24c
|
16
|
|
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, file e14ff6e5-f824-0209-e053-6605fe0ad24c
|
16
|
|
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review, file e14ff6e5-fa63-0209-e053-6605fe0ad24c
|
16
|
|
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells, file e14ff6e5-ff2a-0209-e053-6605fe0ad24c
|
16
|
|
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study, file e14ff6e6-0011-0209-e053-6605fe0ad24c
|
16
|
|
Second-line chemotherapy in advanced biliary cancer: the present now will later be past, file e14ff6e6-0861-0209-e053-6605fe0ad24c
|
16
|
|
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study, file e14ff6e5-fe22-0209-e053-6605fe0ad24c
|
15
|
|
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy, file e14ff6e5-fefe-0209-e053-6605fe0ad24c
|
15
|
|
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?, file e14ff6e6-036f-0209-e053-6605fe0ad24c
|
15
|
|
Severe rhabdomyolysis associated with pemetrexed-based chemotherapy, file e14ff6e6-0829-0209-e053-6605fe0ad24c
|
15
|
|
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck, file e14ff6e6-08b5-0209-e053-6605fe0ad24c
|
15
|
|
COX-2 targeting in cancer: a new beginning?, file e14ff6e6-08ca-0209-e053-6605fe0ad24c
|
15
|
|
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias, file e14ff6e6-0bae-0209-e053-6605fe0ad24c
|
15
|
|
Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells, file e14ff6e6-0bcd-0209-e053-6605fe0ad24c
|
15
|
|
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer, file e14ff6e6-0409-0209-e053-6605fe0ad24c
|
14
|
|
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer, file e14ff6e4-c393-0209-e053-6605fe0ad24c
|
13
|
|
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib, file e14ff6e4-fb11-0209-e053-6605fe0ad24c
|
13
|
|
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder, file e14ff6e5-00d2-0209-e053-6605fe0ad24c
|
13
|
|
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases, file e14ff6e5-fec0-0209-e053-6605fe0ad24c
|
13
|
|
Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb, file e14ff6e5-fec3-0209-e053-6605fe0ad24c
|
13
|
|
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study, file e14ff6e6-03e4-0209-e053-6605fe0ad24c
|
13
|
|
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia, file e14ff6e6-05a2-0209-e053-6605fe0ad24c
|
13
|
|
Renal cancer: new models and approach for personalizing therapy, file e14ff6e6-077e-0209-e053-6605fe0ad24c
|
13
|
|
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients, file e14ff6e6-087e-0209-e053-6605fe0ad24c
|
13
|
|
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study, file e14ff6e6-0bb0-0209-e053-6605fe0ad24c
|
13
|
|
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis, file b37310ff-6710-4735-aed7-4ad6520f41df
|
12
|
|
Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy, file e14ff6e5-f821-0209-e053-6605fe0ad24c
|
12
|
|
Old age: biologic versus chronologic, file e14ff6e5-f992-0209-e053-6605fe0ad24c
|
12
|
|
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma, file e14ff6e5-fe15-0209-e053-6605fe0ad24c
|
12
|
|
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy, file e14ff6e6-00f3-0209-e053-6605fe0ad24c
|
12
|
|
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors, file e14ff6e6-0565-0209-e053-6605fe0ad24c
|
12
|
|
Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study, file e14ff6e6-071b-0209-e053-6605fe0ad24c
|
12
|
|
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer, file e14ff6e6-07bf-0209-e053-6605fe0ad24c
|
12
|
|
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia, file e14ff6e6-086f-0209-e053-6605fe0ad24c
|
12
|
|
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells, file e14ff6e6-0c77-0209-e053-6605fe0ad24c
|
12
|
|
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?, file e14ff6e6-0d56-0209-e053-6605fe0ad24c
|
12
|
| Totale |
2.491 |